Bayer's Vitrakvi (larotrectinib) Receives EMA's Approval as the First Tumor Agonist in Europe
Shots:
- The approval is based on the pooled clinical study including P-I study in adults- P-II NAVIGATE study in adults & adolescents & P-I/II pediatric SCOUT study assessing Vitrakvi in 102 patients (93 patients from the primary analysis population and an additional 9 patients with primary CNS tumors) with solid tumors displaying NTRK gene
- Results: primary analysis population- ORR (72%); CR (16%); PR (55%); Post 1yr. 88% patients were alive; primary CNS patients- ORR (67%); CR & PR (15% & 15%); neither mDOR nor mPFS met at the time of analysis
- Vitrakvi is an oral highly selective TRK inhibitor- already approved in the US- Brazil & Canada. Following LOXO acquisition- Bayer got WW exclusive licensing right to develop & commercialize larotrectinib and the investigational TRK inhibitor BAY 2731954
Click here to read full press release/ article | Ref: Bayer | Image: DW
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com